← Back to Search

Behavioral Intervention

New Approach vs Standard Care for Broken Bones Due to Osteoporosis (RESTORE Trial)

N/A

Waitlist Available

Led By Kenneth Saag, MD, MSc

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 50 years and older (no upper age limit)

Sustained a primary fragility fracture (hip/femur/pelvis, clinical spine, humerus, wrist/forearm) in the last 6 months

Must not have

Exposure to specific medications in the prior 12 months: Actonel or Atelvia (risedronate), Fosamax or Binosto (alendronate), Reclast, Zometa, or Aclasta (zoledronic acid, zoledronate), Boniva or Bondronat (ibandronate), Aredia (pamidronate), Prolia (denosumab), Evenity (romozosumab), Tymlos (abaloparatide), Forteo (teriparatide), Natpara (parathyroid hormone), Evista (raloxifene), Miacalcin (calcitonin)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months post randomization

Awards & highlights

No Placebo-Only Group

Summary

"This trial is comparing a new approach called Augmented-FLS, where patients are contacted by a patient navigator and referred to a bone health provider, to the standard approach called Enhanced Usual Care,

Who is the study for?

The RESTORE trial is for individuals with osteoporosis or those who have recently experienced bone fractures due to the condition. It's open to a diverse group regardless of age, race, ethnicity, sex, poverty level, and location. However, specific details on who can't participate are not provided.

What is being tested?

This study compares two approaches: Augmented-Fracture Liaison Service (FLS) involving a patient navigator and referrals to bone health specialists versus Enhanced Usual Care that focuses on educating patients and primary care providers about bone health.

What are the potential side effects?

Since this trial involves service-based interventions rather than medications or invasive procedures, typical drug-related side effects are not expected. Any potential side effects would likely be related to the individual's response to receiving additional healthcare guidance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 50 years old or older.

Select...

I have had a major bone fracture in the past 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have taken specific bone-related medications in the last year.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months post randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months post randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months post randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of subsequent fracture

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Augmented-Fracture Liaison Service ArmExperimental Treatment1 Intervention

Participants will be mailed education materials. Participants will also be contacted by patient navigators who will guide participants through the process of getting a Bone Health Clinician appointment.

Group II: Enhanced Usual Care ArmActive Control1 Intervention

Participants will be mailed education materials and encouraged to follow up with their primary care physician.

0 / 3Eligibility criteria met